These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8420303)

  • 1. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.
    Miller M; Bachorik PS; McCrindle BW; Kwiterovich PO
    Am J Med; 1993 Jan; 94(1):7-12. PubMed ID: 8420303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
    Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ
    J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein-cholesterol concentrations.
    Rubins HB; Robins SJ
    J Intern Med; 1992 Apr; 231(4):421-6. PubMed ID: 1588269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.
    King JM; Crouse JR; Terry JG; Morgan TM; Spray BJ; Miller NE
    Am J Med; 1994 Oct; 97(4):323-31. PubMed ID: 7942933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
    Hung YJ; Pei D; Wu DA; Kuo SW; Fuh MM; Jeng C
    J Formos Med Assoc; 1999 Feb; 98(2):104-10. PubMed ID: 10083765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
    McKenney JM; Barnett MD; Wright JT; Proctor JP
    Arch Intern Med; 1992 Sep; 152(9):1781-7. PubMed ID: 1520045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein cholesterol elevation with gemfibrozil: effects of baseline level and modifying factors.
    Mänttäri M; Tenkanen L; Mäenpää H; Manninen V; Huttunen JK
    Clin Pharmacol Ther; 1993 Oct; 54(4):437-47. PubMed ID: 8222487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
    Rabkin SW; Hayden M; Frohlich J
    Atherosclerosis; 1988 Oct; 73(2-3):233-40. PubMed ID: 3056431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.
    Simo IE; Yakichuk JA; Ooi TC
    Atherosclerosis; 1993 Apr; 100(1):55-64. PubMed ID: 8318063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
    Bays HE; McKenney JM; Dujovne CA; Schrott HG; Zema MJ; Nyberg J; MacDougall DE;
    Am J Cardiol; 2003 Sep; 92(5):538-43. PubMed ID: 12943873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.